BRD3308 (C09-0785-965)

InformationBRD3308 is a potant and highly selective inhibitor ofHDAC3with IC50 of 54 nM, 1.26 μM and 1.34 μM for HDAC3, HDAC1 and HDAC2, respectively. BRD3308 activates HIV-1 transcription. BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines (glucolipotoxic stress) and increases functional insulin release.TargetsHDAC3 (Cell-free assay); HDAC1 (Cell-free assay); HDAC2 (Cell-free assay) 54 nM; 1.26 μM; 1.34 μMIn vitroBRD3308 is a derivative of the ortho-aminoanilide HDAC inhibitor CI-994 and is developed to be highly selective for inhibition of HDAC3 with an IC50 value that is 23-fold lower for HDAC3 than for HDAC1 or 22. HDAC3 selective inhibition induces expression of HIV and exposure to BRD3308 allows the recovery of latent HIV-1 from patient cells.In vivoSelective inhibition of HDAC3 by BRD3308 prevents diabetes onset in female NOD mice. HDAC3 treatment in vivo prevents pancreatic islet infiltration and protects β-cells from apoptosis. β-cell proliferation is increased in animals treated with BRD3308. HDAC3 treatment in vivo prevents white adipose tissue infiltration in NOD mice.Cell Research(from reference)Cell lines：2D10 cells, J89 cells, THP89 cells, J-Lat 6.3 cells Concentrations：5 μM, 10 μM, 15 μM, 30 μM Incubation Time：6 h, 12 h, 18 h, 24 h. Specification: 0.97 Molecular Formula: C15H14FN3O2 Molecular Weight: 287.29 PubChem CID: 72734382 Isomeric SMILES: CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)F)N